SYNGENE384.00

Syngene International Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹15,471 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations3,488.63,642.43,738.73,600.2
Other Income90.671.870.778.3
Total Income3,579.23,714.23,809.43,678.5
Expenses
+ Cost of Materials Consumed873.6925.4911.2849.9
+ Changes in Inventories56.617.17.424.5
+ Employee Benefit Expense888.7983.91,104.91,102.3
+ Finance Costs47.253.148.846.8
+ Depreciation & Amortisation425.9432.6452.9453.9
+ Other Expenses655.3674.2796.7820.6
Total Expenses2,947.33,086.33,321.93,298.0
EBITDA1,014.41,041.8918.5802.9
EBIT588.5609.2465.6349.0
Profit
PBT before Exceptional Items631.9627.9487.5380.5
+ Exceptional Items-11.132.0-76.6-90.1
Pretax Income620.8659.9410.9290.4
+ Current Tax123.0138.487.064.3
+ Deferred Tax-12.225.37.25.1
Tax Expense110.8163.794.269.4
Net Income510.0496.2316.7221.0
+ Net Income — Continuing Ops510.0496.2316.7221.0
+ Other Comprehensive Income142.6-14.7-196.0-182.1
Total Comprehensive Income652.6481.5120.738.9
Per Share
Basic EPS12.7112.357.875.50
Diluted EPS12.6912.347.875.49
Other Comprehensive Income — detail
+ Other Comprehensive Income-14.7-196.0-182.1
+ Items NOT to be Reclassified to P&L-11.92.9-6.3-7.2
+ Tax on Items NOT to be Reclassified0.9-1.6-1.9
+ Tax on Items NOT to be Reclassified — alt tag-3.9
+ Items to be Reclassified to P&L199.3-21.1-267.9-248.8
+ Tax on Items to be Reclassified-4.4-76.6-72.0
+ Tax on Items to be Reclassified — alt tag48.7
Per Share — as-filed variants
Basic EPS — Continuing Operations12.7112.357.875.50
Diluted EPS — Continuing Operations12.6912.347.875.49
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit2,558.42,699.92,820.12,725.8
Gross Margin %73.3474.1275.4375.71
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)631.9627.9487.5380.5
− Exceptional Items (reconciliation)-11.132.0-76.6-90.1
Net Income Adj (tax-effected)519.1472.1375.7289.6
EPS Adj12.9411.759.347.21
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital402.0402.5402.9403.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.